Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Prostate Cancer

  Free Subscription


Articles published in Br J Radiol

Retrieve available abstracts of 53 articles:
HTML format
Text format



Single Articles


    July 2019
  1. KIM SJ, Lee SW
    Diagnostic accuracy of (F)18 flucholine PET/CT for preoperative lymph node staging in newly diagnosed prostate cancer patients; a systematic review and meta-analysis.
    Br J Radiol. 2019 Jul 5:20190193. doi: 10.1259/bjr.20190193.
    PubMed     Text format     Abstract available


  2. KISHAN AU, Tyran M, Weng J, Upadhyaya S, et al
    Stereotactic body radiotherapy to the prostate and pelvic lymph nodes: A detailed dosimetric analysis of a phase II prospective trial.
    Br J Radiol. 2019;92:20181001.
    PubMed     Text format     Abstract available


    June 2019
  3. ACAR E, Leblebici A, Ellidokuz BE, Basbinar Y, et al
    Machine learning for differentiating metastatic and completely responded sclerotic bone lesion in prostate cancer: A retrospective radiomics study.
    Br J Radiol. 2019 Jun 20:20190286. doi: 10.1259/bjr.20190286.
    PubMed     Text format     Abstract available


  4. SUREKA B, Elhence P, Khera PS, Choudhary GR, et al
    Quantitative contrast-enhanced perfusion kinetics in multiparametric MRI in differentiating prostate cancer from chronic prostatitis: results from a pilot study.
    Br J Radiol. 2019 Jun 11:20190181. doi: 10.1259/bjr.20190181.
    PubMed     Text format     Abstract available


  5. DE LEON J, Jameson MG, Rivest-Henault D, Keats S, et al
    Reduced motion and improved rectal dosimetry through endorectal immobilization for prostate stereotactic body radiotherapy.
    Br J Radiol. 2019;92:20190056.
    PubMed     Text format     Abstract available


    April 2019
  6. TAMPONI M, Gabriele D, Maggio A, Stasi M, et al
    Prostate cancer dose-response, fractionation sensitivity and repopulation parameters evaluation from 25 international radiotherapy outcome data sets.
    Br J Radiol. 2019 Apr 24:20180823. doi: 10.1259/bjr.20180823.
    PubMed     Text format     Abstract available


  7. LEE SM, Wolfe K, Acher P, Liyanage SH, et al
    Multiparametric MRI appearances of primary granulomatous prostatitis.
    Br J Radiol. 2019 Apr 9:20180075. doi: 10.1259/bjr.20180075.
    PubMed     Text format     Abstract available


    March 2019
  8. WANG T, Press RH, Giles M, Jani AB, et al
    Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy.
    Br J Radiol. 2019 Mar 26:20190089. doi: 10.1259/bjr.20190089.
    PubMed     Text format     Abstract available


  9. KING AJ, Dudderidge T, Darekar A, Schimitz K, et al
    Establishing magnetic resonance imaging guided prostate intervention at a UK Centre.
    Br J Radiol. 2019 Mar 26:20180918. doi: 10.1259/bjr.20180918.
    PubMed     Text format     Abstract available


  10. JI Y, Litao R, Ren W, Dun G, et al
    Stiffness of prostate gland measured by transrectal Real-Time shear wave elastography for detection of prostate cancer: A feasibility study.
    Br J Radiol. 2019 Mar 15:20180970. doi: 10.1259/bjr.20180970.
    PubMed     Text format     Abstract available


  11. FRANZESE C, D'agostino G, Di Brina L, Navarria P, et al
    Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity.
    Br J Radiol. 2019 Mar 13:20190021. doi: 10.1259/bjr.20190021.
    PubMed     Text format     Abstract available


  12. PIERRE DE M, Roberto Luigi C, Julien G, Thibault T, et al
    Percutaneous MR-guided whole-gland prostate cancer cryoablation: safety considerations and oncologic results in 30 consecutive patients.
    Br J Radiol. 2019 Mar 8. doi: 10.1259/bjr.20180965.
    PubMed     Text format     Abstract available


    February 2019
  13. WANG H, Cooper BT, Schiff P, Sanfilippo NJ, et al
    Dosimetric assessment of tumor control probability in intensity and volumetric modulated radiotherapy plans.
    Br J Radiol. 2019;92:20180471.
    PubMed     Text format     Abstract available


    January 2019
  14. PATHMANATHAN AU, McNair HA, Schmidt MA, Brand DH, et al
    Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy.
    Br J Radiol. 2019 Jan 24:20180948. doi: 10.1259/bjr.20180948.
    PubMed     Text format     Abstract available


  15. COHEN J, Anvari A, Samanta S, Poirier Y, et al
    Mild hyperthermia as a localized radiosensitizer for deep-seated tumors: Investigation in an orthotopic prostate cancer model in mice.
    Br J Radiol. 2019 Jan 23:20180759. doi: 10.1259/bjr.20180759.
    PubMed     Text format     Abstract available


    December 2018
  16. NANDURKAR R, van Leeuwen P, Stricker P, Woo H, et al
    (68)Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery.
    Br J Radiol. 2018 Dec 19:20180667. doi: 10.1259/bjr.20180667.
    PubMed     Text format     Abstract available


    November 2018
  17. GIACOMETTI V, King RB, Agnew CE, Irvine DM, et al
    An Evaluation of Techniques for Dose Calculation on Cone Beam Computed Tomography.
    Br J Radiol. 2018 Nov 15:20180383. doi: 10.1259/bjr.20180383.
    PubMed     Text format     Abstract available


  18. TAU N, Berlin A, Yeung I, Halankar J, et al
    Quantitative assessment of dynamic (18)F-Fluoromethycholine PET and Dynamic Contrast Enhanced MRI in High Risk Prostate Cancer.
    Br J Radiol. 2018 Nov 1:20180568. doi: 10.1259/bjr.20180568.
    PubMed     Text format     Abstract available


  19. TURNER JH
    Recent advances in theranostics and challenges for the future.
    Br J Radiol. 2018;91:20170893.
    PubMed     Text format     Abstract available


    October 2018
  20. JERECZEK-FOSSA BA, Rojas DP, Zerini D, Fodor C, et al
    Re-irradiation for isolated local recurrence of prostate cancer: MONO-INSTITUTIONAL series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT).
    Br J Radiol. 2018 Oct 31:20180494. doi: 10.1259/bjr.20180494.
    PubMed     Text format     Abstract available


    September 2018
  21. HEDGIRE S, Kilcoyne A, Tonyushkin A, Mao Y, et al
    Effect of androgen deprivation and radiation therapy on MRI fiber tractography in prostate cancer: Can we assess treatment response on imaging?
    Br J Radiol. 2018 Sep 13:20170170. doi: 10.1259/bjr.20170170.
    PubMed     Text format     Abstract available


    July 2018
  22. AZADI J, Nguyen ML, Leroy A, Macura KJ, et al
    The emerging role of imaging in prostate cancer secondary screening: multiparametric magnetic resonance imaging and the incipient incorporation of molecular imaging.
    Br J Radiol. 2018 Jul 26:20170960. doi: 10.1259/bjr.20170960.
    PubMed     Text format     Abstract available


    June 2018
  23. MULLANEY L, O'Shea E, Dunne MT, Thirion PG, et al
    A comparison of bladder volumes based on treatment planning Computed Tomography and BladderScan(R) BVI 6100 ultrasound device in a prostate radiation therapy population.
    Br J Radiol. 2018 Jun 11:20180160. doi: 10.1259/bjr.20180160.
    PubMed     Text format     Abstract available


  24. NGUYEN TB, Ushinsky A, Yang A, Nguyentat M, et al
    Utility of quantitative apparent diffusion coefficient measurements and normalized apparent diffusion coefficient ratios in the diagnosis of clinically significant peripheral zone prostate cancer.
    Br J Radiol. 2018 Jun 5:20180091. doi: 10.1259/bjr.20180091.
    PubMed     Text format     Abstract available


  25. MARTIN JM, Supiot S, Keall PJ, Catton CN, et al
    Moderately hypofractionated prostate external-beam radiotherapy: an emerging standard.
    Br J Radiol. 2018;91:20170807.
    PubMed     Text format     Abstract available


    May 2018
  26. KULKARNI HR, Singh A, Langbein T, Schuchardt C, et al
    Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
    Br J Radiol. 2018 May 15:20180308. doi: 10.1259/bjr.20180308.
    PubMed     Text format     Abstract available


  27. TIMON G, Ciardo D, Bazani A, Marvaso G, et al
    Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of phase II trial AIRC-IG-13218.
    Br J Radiol. 2018 May 11:20160725. doi: 10.1259/bjr.20160725.
    PubMed     Text format     Abstract available


    April 2018
  28. JADVAR H, Colletti PM
    (18)F-NaF/(223)RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome.
    Br J Radiol. 2018 Apr 9:20170948. doi: 10.1259/bjr.20170948.
    PubMed     Text format     Abstract available


    March 2018
  29. JUNG SI, Jeon HJ, Park HS, Yu MH, et al
    Multiparametric MR imaging of peripheral zone prostate cancer: effect of postbiopsy hemorrhage on cancer detection according to Gleason score and tumour volume.
    Br J Radiol. 2018 Mar 9:20180001. doi: 10.1259/bjr.20180001.
    PubMed     Text format     Abstract available


    February 2018
  30. GODDARD L, Brodin NP, Bodner WR, Garg M, et al
    Comparing photon and proton based hypofractioned sbrt for prostate cancer accounting for robustness and realistic treatment deliverability.
    Br J Radiol. 2018 Feb 13:20180010. doi: 10.1259/bjr.20180010.
    PubMed     Text format     Abstract available


  31. KING RB, Osman SO, Fairmichael C, Irvine DM, et al
    Efficacy of a rectal spacer with prostate SABR-first UK experience.
    Br J Radiol. 2018;91:20170672.
    PubMed     Text format     Abstract available


  32. DI PAOLA V, Cybulski A, Belluardo S, Cavicchioli F, et al
    Evaluation of periprostatic neurovascular fibers before and after radical prostatectomy by means of 1.5 t mri diffusion tensor imaging.
    Br J Radiol. 2018 Feb 1:20170318. doi: 10.1259/bjr.20170318.
    PubMed     Text format     Abstract available


    January 2018

  33. Addendum to Hricak H. MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. Br J Radiol 2005; 78: S103-S111.
    Br J Radiol. 2018 Jan 31:bjr11253478a. doi: 10.1259/bjr.11253478.
    PubMed     Text format    


  34. DUFFTON A, Sadozye A, Devlin L, MacLeod N, et al
    Safety and feasibility of prostate stereotactic ablative radiotherapy using multi-modality imaging and flattening filter free.
    Br J Radiol. 2018 Jan 17:20170625. doi: 10.1259/bjr.20170625.
    PubMed     Text format     Abstract available


  35. ELFATAIRY KK, Filson CP, Sanda MG, Osunkoya AO, et al
    In-bore MRI-guided biopsy: can it optimize the need for periodic biopsies in prostate cancer patients undergoing active surveillance? a pilot test-retest reliability study.
    Br J Radiol. 2018 Jan 8:20170603. doi: 10.1259/bjr.20170603.
    PubMed     Text format     Abstract available


  36. TEOH EJ, McGowan DR, Schuster DM, Tsakok M, et al
    Bayesian penalised likelihood reconstruction (Q.Clear) of (18)F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation.
    Br J Radiol. 2018 Jan 5:20170727. doi: 10.1259/bjr.20170727.
    PubMed     Text format     Abstract available


  37. DENIS-BACELAR AM, Chittenden SJ, McCready VR, Divoli A, et al
    Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.
    Br J Radiol. 2018 Jan 2:20170795. doi: 10.1259/bjr.20170795.
    PubMed     Text format     Abstract available


    December 2017
  38. BOUSTANI AM, Pucar D, Saperstein L
    Molecular imaging of prostate cancer.
    Br J Radiol. 2017 Dec 15:20170736. doi: 10.1259/bjr.20170736.
    PubMed     Text format     Abstract available


    November 2017
  39. BRIZMOHUN APPAYYA M, Sidhu HS, Dikaios N, Johnston EW, et al
    Characterizing indeterminate (Likert-scored 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multi-parametric MRI.
    Br J Radiol. 2017 Nov 30:20170645. doi: 10.1259/bjr.20170645.
    PubMed     Text format     Abstract available


  40. TOMITA N, Soga N, Ogura Y, Furusawa J, et al
    Effects of dose-escalated radiotherapy in combination with long-term androgen deprivation on prostate cancer.
    Br J Radiol. 2017 Nov 22:20170431. doi: 10.1259/bjr.20170431.
    PubMed     Text format     Abstract available


  41. TANAKA O, Komeda H, Tamaki M, Seike K, et al
    Comparison of MRI visualisation between linearly placed iron-containing and non-iron-containing fiducial markers for prostate radiotherapy.
    Br J Radiol. 2017 Nov 9:20170612. doi: 10.1259/bjr.20170612.
    PubMed     Text format     Abstract available


  42. PIZARRO F, Hernandez A
    Optimization of radiotherapy fractionation schedules based on radiobiological functions.
    Br J Radiol. 2017;90:20170400.
    PubMed     Text format     Abstract available


  43. CIARDO D, Jereczek-Fossa BA, Petralia G, Timon G, et al
    Multimodal image registration for the identification of dominant intraprostatic lesion in high-precision radiotherapy treatments.
    Br J Radiol. 2017;90:20170021.
    PubMed     Text format     Abstract available


    August 2017
  44. KWON MR, Kim CK, Kim JH
    PI-RADS version 2: Evaluation of diffusion-weighted imaging interpretation between B = 1000 and B = 1500 s/mm2.
    Br J Radiol. 2017 Aug 22:20170438. doi: 10.1259/bjr.20170438.
    PubMed     Text format     Abstract available


    July 2017
  45. SAMLALI H, Udrescu C, Lapierre A, Enachescu C, et al
    Prospective evaluation of a specific technique of sexual function preservation in external beam radiotherapy for prostate cancer.
    Br J Radiol. 2017 Jul 27:20160877. doi: 10.1259/bjr.20160877.
    PubMed     Text format     Abstract available


  46. HAUTH E, Halbritter D, Jaeger H, Hohmuth H, et al
    Diagnostic value of semiquantitative and quantitative analysis of functional parameters in multiparametric MRI of the prostate.
    Br J Radiol. 2017 Jul 27:20170067. doi: 10.1259/bjr.20170067.
    PubMed     Text format     Abstract available


  47. GERLACH S, Kuhlemann I, Ernst F, Furweger C, et al
    Impact of robotic ultrasound image guidance on plan quality in SBRT of the prostate.
    Br J Radiol. 2017 Jul 27:20160926. doi: 10.1259/bjr.20160926.
    PubMed     Text format     Abstract available


    June 2017
  48. FLUX GD
    Imaging and dosimetry for radium-223: the potential for personalized treatment.
    Br J Radiol. 2017 Jun 27:20160748. doi: 10.1259/bjr.20160748.
    PubMed     Text format     Abstract available


    May 2017
  49. GASNIER A, Parvizi N
    Updates on the diagnosis and treatment of prostate cancer.
    Br J Radiol. 2017 May 30:20170180. doi: 10.1259/bjr.20170180.
    PubMed     Text format     Abstract available


  50. ROBINSON JL, Tzou KS, Parker AS, Heckman MG, et al
    GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer.
    Br J Radiol. 2017 May 9:20170174. doi: 10.1259/bjr.20170174.
    PubMed     Text format     Abstract available


    January 2017
  51. HARVEY H, Orton MR, Morgan VA, Parker C, et al
    Volumetry of the Dominant Intraprostatic Tumour Lesion: Intersequence and Interobserver Differences on Multiparametric MRI.
    Br J Radiol. 2017 Jan 5:20160416. doi: 10.1259/bjr.20160416.
    PubMed     Text format     Abstract available


    December 2016
  52. CHAN J, Carver A, Brunt JN, Vinjamuri S, et al
    Effect of androgen deprivation therapy on intra-prostatic tumour volume identified on 18F choline PET/CT for prostate dose painting radiotherapy.
    Br J Radiol. 2016 Dec 20:20160818.
    PubMed     Text format     Abstract available


    November 2016
  53. LJUNGBERG M, Pretorius PH
    SPECT/CT: an update on technological developments and clinical applications.
    Br J Radiol. 2016 Nov 15:20160402.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: